Home › Marginal Zone Lymphoma › Oregon › Portland
Marginal Zone Lymphoma clinical trials in Portland, OR
5 studies for Marginal Zone Lymphoma are looking for participants at sites in and around Portland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RecruitingPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- Oregon Health & Science University, Portland
Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
- Oregon Health and Science University - Knight Cancer Institute, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Portland
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecruitingPhase 1
- Oregon Health & Science University, Portland
Marginal Zone Lymphoma trials in other cities
- Durham, NC12 studies
- New York City, NY11 studies
- Seattle, WA9 studies
- Boston, MA9 studies
- Milwaukee, WI9 studies
- Baldwin Park, CA9 studies
- Rochester, MN8 studies
- Edison, NJ8 studies
- Columbus, OH8 studies
- Houston, TX8 studies
- Miami, FL7 studies
- Denver, CO7 studies
Other studies in Portland
- Non-Small Cell Lung Cancer46 studies
- Cancer (all types)34 studies
- Prostate Cancer33 studies
- Breast Cancer33 studies
- Metastatic Cancer29 studies
- Colorectal Cancer28 studies
- Ovarian Cancer27 studies
- Lung Cancer26 studies
- Acute Myeloid Leukemia25 studies
- Endometrial Cancer24 studies
- Head and Neck Squamous Cell Carcinoma19 studies
- Pancreatic Cancer19 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.